Request Demo
Last update 18 Jul 2025
Pembrolizumab Biosimilar(Celltrion)
Last update 18 Jul 2025
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms Pembrolizumab Biosimilar (Celltrion, Inc.), CT-P51, CTP51 |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 93660H
The sequence is quoted from: *****
Sequence Code 93670L
The sequence is quoted from: *****
Related
3
Clinical Trials associated with Pembrolizumab Biosimilar(Celltrion)CTIS2024-514048-98-00
A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P51 and Keytruda in Combination with Platinum-Pemetrexed Chemotherapy in Patients with Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer - CT-P51 3.1
NCT06939595
A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P51 and Keytruda in Combination With Platinum-Pemetrexed Chemotherapy in Patients With Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer
CTIS2023-510017-26-00
- CT-P51 1.1
100 Clinical Results associated with Pembrolizumab Biosimilar(Celltrion)
Login to view more data
100 Translational Medicine associated with Pembrolizumab Biosimilar(Celltrion)
Login to view more data
100 Patents (Medical) associated with Pembrolizumab Biosimilar(Celltrion)
Login to view more data
100 Deals associated with Pembrolizumab Biosimilar(Celltrion)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metastatic Lung Cancer | Phase 3 | Georgia | 30 Jan 2025 | |
| Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 3 | Georgia | 30 Jan 2025 | |
| Lung Cancer | IND Application | United States | 24 Jun 2024 | |
| Melanoma | IND Application | United States | 24 Jun 2024 | |
| Stomach Cancer | IND Application | United States | 24 Jun 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free